Homepage
Open in app
Sign in
Get started
Biotech Valuation
Stories and thoughts on healthcare valuation from Nealon Biotech.
Follow
The Future of Cardiac Gene Therapy
The demise of Celladon and the evaporation of $360,000,000
Brad Plummer PhD
Apr 28, 2015
Atrial Fibrillation in 2015: Burn it All
Atrial fibrillation (AF) is the most common irregular heart rhythm (e.g. arrhythmia) and will affect 1 in 4 people.
Brad Plummer PhD
Feb 4, 2015
Cellular Dynamics International at #JPM15: Time for iPSC therapies?
Robert Palay, CEO and Emile Newaysir, COO for Cellular Dynamics Technology (CDI, $ICEL) took the stage Wednesday, January 14th at the J.P…
Brad Plummer PhD
Jan 16, 2015
About Biotech Valuation
Latest Stories
Archive
About Medium
Terms
Privacy
Teams
